Abstracts

Cumulative Viral Load Predicts All-Cause and AIDS-Related Mortality After Initiation of ART

Background: The prognostic value of cross-sectional viral load (VL) measures for clinical events following ART initiation is well established but the best way to quantify their association with clinical events and death over time is unclear. Methodology: Treatment-naive patients starting ART between January 2000 and December 2009 in one of 17 cohorts participating in the…

Long Term Effects of Treatment Interruptions in Adults and Children

Background: Stockouts are relatively common in large ART programmes and cause treatment interruptions, but their long-term impact is rarely assessed. We investigated this using long-term follow-up of a structured treatment interruption (STI) randomization 12 weeks on/off in a large adult trial (DART), and data on unplanned treatment interruptions (UPTIs) in this and a parallel paediatric…

Multi-System Investigation of the Mechanisms for Raltegravir Association With Intestinal Tissue

Background: Recent data have suggested that concentrations of raltegravir (RAL) in gut tissue are high after oral administration to humans, with implications for treatment and prevention. We have used in silico, in vitro, ex vivo and in vivo models to further investigate the accumulation of RAL in gut tissue. Methodology: Gut-to-plasma affinity was predicted in…

Tenofovir DF 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Impairment

Background: Renal impairment significantly alters tenofovir pharmacokinetics. The recommended tenofovir disoproxil fumarate (TDF) dose is 300 mg every 48 hours for adults with moderate renal function impairment (creatinine clearance 30-49 mL/min). New dosage strengths and formations of TDF may permit once daily dosing for these patients. We compared the pharmacokinetics of TDF 300 mg every…